Aczone Restricted Indication Could Be Lifted Pending Phase IV Data
Executive Summary
QLT believes results from a Phase IV trial will allow the company to remove restrictive screening language in labeling for its recently approved topical gel acne treatment Aczone (dapsone)
You may also be interested in...
Novartis To Maintain Sales Force In Face Of Potential Competitor Cutbacks
Novartis' decision to maintain its current sales force level could reflect the company's confidence in the continued growth of its pharmaceutical business
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials